Study of a new pill for advanced prostate cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new oral drug, XNW5004, for men with advanced prostate cancer that has spread or stopped responding to standard treatments. It may be given alone or with other therapies like abiraterone, enzalutamide, or chemotherapy, and aims to find better ways to control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- You have a confirmed diagnosis of prostate cancer that has spread to bones or other tissues and has progressed despite current treatments.
- You have had hormone therapy (like Lupron) or surgery to lower testosterone, and your testosterone is at castrate levels.
- You have not received certain prior treatments (depends on which group you join), and you agree to use contraception during the study.
- Your liver, kidney, and blood counts must be within specific limits.
- You must be able to participate in study procedures and follow the plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This Phase 1 trial tests HRS-5041 in people with metastatic castration-resistant prostate cancer (prostate cancer that keeps growing despite lower testosterone). It aims to see if the drug can be given safely and whether it may help control the cancer after prior standard treatments.
This trial tests a new drug, XNW5004, combined with enzalutamide for men with metastatic castration-resistant prostate cancer that has progressed despite other treatments. It aims to see if this combination can slow the cancer's growth.
This study tests an experimental drug, alone or with other treatments, for men with advanced prostate cancer that has stopped responding to standard therapies. The goal is to see if it can shrink tumors or slow the disease.
This study tests an experimental drug called XNW34017 in people with advanced or metastatic solid tumors, especially small cell lung cancer and prostate cancer that have progressed despite prior treatments. The goal is to see if the drug is safe and effective for these cancers.
This trial tests an experimental drug, GLR2037, for men with advanced prostate cancer that has spread to the bones or soft tissue and has progressed despite prior treatments. The drug may help slow the cancer's growth.
Hear when a new Advanced Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.